KRAS and lung carcinoma: Our findings reveal a novel pathway critical for the regulation of SIRT1 activity in KRAS<sup>Mut</sup> lung cancer and provide important evidence for the potential application of SIRT1 activity inhibitors as an adjuvant chemotherapy, overcoming chemoresistance in patients with KRAS<sup>Mut</sup> lung cancer.